MUMBAI, India, May 1 -- Intellectual Property India has published a patent application (202611025764 A) filed by Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, on March 5, for 'nanostructured, enzyme-inhibitor-coordinated, mucoadhesive oral peptide delivery composition and method for transient localized protease suppression, controlled intestinal release, and enhanced systemic bioavailability.'
Inventor(s) include Mr. Nishant Gaurav; Dr. Sumita Singh; Mr. Vishal Kumar Biswkarma; and Mr. Sachin Kumar.
The application for the patent was published on May 1, under issue no. 18/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to an enzyme-inhibitor-coordinated, mucoadhesive nanostructured oral peptide delivery system designed to enhance intestinal bioavailability of peptide therapeutics. The system comprises peptide-loaded biodegradable nanocarriers co-encapsulating one or more reversible protease inhibitors, dispersed within a polymeric matrix and enclosed within a pH-triggered enteric coating. The formulation remains stable under gastric conditions and undergoes selective dissolution at intestinal pH (5.5-6.8), enabling synchronized release of the peptide and inhibitor in the upper small intestine. The coordinated release provides transient localized suppression of gastrointestinal proteases for 60-120 minutes, thereby reducing enzymatic degradation during a defined absorption window. A mucoadhesive polymer enhances intestinal residence time and epithelial interaction, facilitating systemic uptake. The system achieves significantly reduced peptide degradation, extended half-life, and improved oral bioavailability without permanent enzyme inhibition. The invention provides a scalable, non-invasive alternative to injectable peptide therapies, improving patient compliance and therapeutic efficacy in chronic disease management."
Disclaimer: Curated by HT Syndication.
